Home >> ESI-09
Related Products
ESI-09 EPAC inhibitor, specific

Catalog No.B4814
Size Price Stock Qty
10mM (in 1mL DMSO)
$90.00
In stock
5mg
$68.00
In stock
25mg
$208.00
In stock
100mg
$474.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

ESI-09

Protocol

Cell experiment [1,2]:

Cell lines

AsPC-1 and PANC-1 pancreatic cancer cells, INS-1 cells

Preparation method

The solubility of this compound in DMSO is > 16.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10 μM, 5 minutes

Applications

ESI-09 (1 μM, 10 μM, 5 minutes) inhibited EPAC-mediated Akt phosphorylation in AsPC-1 pancreatic cancer cells. ESI-09 (5 μM, 10 μM) inhibited EPAC2-mediated insulin secretion in INS-1 cells. ESI-09 (5 μM, 10 μM) inhibited pancreatic cancer migration. In both AcPC-1 and PANC-1 cells, pretreatment with ESI-09 (15 minutes) decreased 007-AM-induced cell adhesion dose-dependently. ESI-09 significantly reduced intracellular and total bacterial counts in human umbilical vein endothelial cells.

Animal experiment [2]:

Animal models

C57BL/6 Epac1 null mice

Dosage form

Intraperitoneal injection, 10 mg/kg/d, 5 d

Application

Treatment with ESI-09 (10 mg/kg/d, i.p.) for 5 days protected WT C57BL/6 mice from fatal SFG rickettsiosis via pharmacological inhibition of EPAC1.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Almahariq M, Tsalkova T, Mei F C, et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion[J]. Molecular pharmacology, 2013, 83(1): 122-128.

[2]. Gong B, Shelite T, Mei F C, et al. Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses[J]. Proceedings of the National Academy of Sciences, 2013, 110(48): 19615-19620.

ESI-09 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ESI-09 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 263707-16-0 SDF Download SDF
Chemical Name (1E)-2-(5-tert-butyl-1,2-oxazol-3-yl)-N-(3-chloroanilino)-2-oxoethanimidoyl cyanide
Canonical SMILES CC(C)(C)C1=CC(=NO1)C(=O)C(=NNC2=CC(=CC=C2)Cl)C#N
Formula C16H15ClN4O2 M.Wt 330.77
Solubility >33.1mg/ml in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

ESI-09 is a specific inhibitor of EPAC with IC50 values of 1.4 and 3.2 µM for EPAC2 and EPAC1, respectively [1].

cAMP/cAMP regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) is a guanine nucleotide exchange factor for small GTPases Rap1 and Rap2 in response to intracellular cAMP [2].

ESI-09 is a specific EPAC inhibitor. ESI-09 (25 µM) reduced EPAC1 and EPAC2 GEF activity to basal levels in the presence of 25 µM cAMP. In the presence of 25 µM cAMP, ESI-09 inhibited cAMP-mediated EPAC2 and EPAC1 GEF activity with IC50 values of 1.4 and 3.2 µM respectively and exhibited 100 times selectivity than PKA. In the pancreatic cancer cell line AsPC-1, ESI-09 inhibited Akt phosphorylation at T308 and S473 stimulated by 007-AM in a dose dependent way. In pancreatic endocrine β cells, ESI-09 inhibited the increase of insulin secretion stimulated by 007-AM in a dose dependent way. In pancreatic cancer cell lines AsPC-1 and PANC-1, ESI-09 significantly reduced cell migration through the inhibition of EPAC1 [1]. In the presence of 20 µM cAMP, ESI-09 inhibited cAMP-mediated EPAC2 and EPAC1 GEF activity with IC50 values of 4.4 and 10.8 µM, respectively [2].

References:
[1].  Almahariq M, Tsalkova T, Mei FC, et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol, 2013, 83(1): 122-128.
[2].  Zhu Y, Chen H, Boulton S, et al. Biochemical and pharmacological characterizations of ESI-09 based EPAC inhibitors: defining the ESI-09 ""therapeutic window"". Sci Rep, 2015, 5: 9344.